Upgrade to SI Premium - Free Trial

H.C. Wainwright Downgrades Fulcrum Therapeutics (FULC) to Neutral

June 2, 2026 6:07 AM
H.C. Wainwright analyst Andrew Fein downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Buy to Neutral with a price target of $3.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades